GU Cancers 2021 | Neoadjuvant atezolizumab for non-metastatic urothelial cancer
Vadim Koshkin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the Phase II trial (NCT02451423) evaluating escalating doses of neoadjuvant atezolizumab for patients with muscle-invasive bladder cancer (MIBC) prior to radical cystectomy. 20 patients with MIBC participated in the trial. Among evaluable patients, the 2-year relapse-free survival (RFS) was 64% and overall survival (OS) was 75%. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Vadim Koshkin, MD, has served in a consulting or advisory role for AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seattle Genetics/Astellas and Dendreon; has received institutional research funding from Endocyte, Nektar, Clovis, Janssen and Taiho; and has received grant funding from the Prostate Cancer Foundation.
